Glucotrack carves out a $900K note with a variable-price conversion, piling dilution risk onto a stock already scraping 52-week lows
GCTK is trading near its 52-week low of $0.287 (1.4% above the low).
Summary
Glucotrack partitioned a $900,000 promissory note and gave the holder the right to convert it into common stock at a variable price with no floor, creating a dilution overhang as the stock trades near all-time lows.
Key Events · Financing and Capital Events · GCTK
-
$900K Note Partitioned with Variable Conversion
On July 22, 2026, Glucotrack partitioned a new $900,000 promissory note from its existing $2.012M note. The holder can convert it into common stock at the lower of the last closing price or the 5-day average, with no floor price.
-
Highly Dilutive Structure Near 52-Week Low
At the current $0.2911 stock price, the $900,000 note could convert into approximately 3.09 million shares — roughly 38% of the 8.06 million shares outstanding, though the 9.99% beneficial ownership cap limits immediate issuance.
-
Free-Trading Shares Expected
The exchange shares are issued under Section 3(a)(9) and are expected to be free-trading under Rule 144, with the holding period tacked back to the original September 2025 note issuance, allowing the investor to sell immediately upon conversion.
-
Follows Reverse Merger and Delisting Threat
This financing comes weeks after a reverse merger with Lokahi Therapeutics that gave Lokahi 90% control, and amid a going-concern warning and Nasdaq delisting proceedings due to sub-$1 stock price and equity shortfall.
Analysis · GCTK · Industrial Applications And Services
From its remaining $2.012 million promissory note, Glucotrack carved out a $900,000 piece and granted the holder the right to convert it into common stock at the lower of the last closing price or the five-day average. Because there is no floor price, a falling stock simply hands the investor more shares — a mechanism that can speed up dilution and weigh on the stock. The shares are expected to be free-trading, so the investor can sell right away. This move lands just weeks after a reverse merger that gave 90% control to Lokahi Therapeutics, and against a backdrop of a going-concern warning and a Nasdaq delisting threat. With the stock trading near its 52-week low of $0.287, even a modest conversion could prove highly dilutive.
At the time of this filing, GCTK was trading at $0.29 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.29 to $14.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.